Eunyoung Lee

Dr. Eunyoung Lee

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2019 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
MCMihong Choi
Mihong Choi
JLJeong-Ok Lee
Jeong-Ok Lee
JJJongheon Jung
Jongheon Jung
JLJi Yun Lee
Ji Yun Lee
ELEunyoung Lee
Eunyoung Lee
JLJong Seok Lee
Jong Seok Lee
Background: Peripheral T cell lymphoma (PTCL) is a heterogeneous entity with poor survival. We evaluated the neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and platelet count as new prognostic factors for PTCL. Patients and Methods: We retrospectively analyzed 77 patients with PTCL initially treated with anthracycline-based chemotherapy. Survival curves were compared between groups with different initial NLR (iNLR), end-point NLR (eNLR), initial ALC, and platelet counts. Cox regression was used to analyze the risk factor for survival. Results: Patients with a higher eNLR (≥3), lymphopenia (< 1,000/μL), and thrombocytopenia (< 150 K/μL) had an inferior progression-free survival (PFS) and overall survival (OS) compared to their counterparts, while a higher iNLR (≥3) was predictive of a shorter OS but not PFS. Among these, thrombocytopenia was an independent poor prognostic factor for both PFS and OS, with a hazard ratio of 2.42 (p = 0.012) for PFS and 4.21 (p = 0.006) for OS. The presence of thrombocytopenia further stratified patients with a worse prognosis within overlapping risk-groups by the prognostic index for PTCL. Conclusions: Our study showed that thrombocytopenia at diagnosis was an independent prognostic factor for survival in patients with PTCL.

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
ELEunyoung Lee
Eunyoung Lee
YKYoungil Koh
Youngil Koh
JHJunshik Hong
Junshik Hong
HEHyeon-Seok Eom
Hyeon-Seok Eom
SYSung-Soo Yoon
Sung-Soo Yoon
Lee E, et al. J Korean Med Sci. 2021 Mar;36(13):e85. https://doi.org/10.3346/jkms.2021.36.e85

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JJJongheon Jung
Jongheon Jung
HLHyewon Lee
Hyewon Lee
YSYang-Gun Suh
Yang-Gun Suh
HEHyeon-Seok Eom
Hyeon-Seok Eom
ELEunyoung Lee
Eunyoung Lee
Jung J, et al. J Korean Med Sci. 2021 Jan;36(8):e55. https://doi.org/10.3346/jkms.2021.36.e55

18 December 2023 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
BPBoyoung Park
Boyoung Park
ELEunyoung Lee
Eunyoung Lee
JYJunghyun Yoon
Junghyun Yoon
YPYoungJu Park
YoungJu Park
HEHyeon-Seok Eom
Hyeon-Seok Eom
This study investigated the incidence of secondary malignancy in multiple myeloma (MM) patients compared with that in the general population using a population-based database covering all residents in Korea. Based on the national health insurance system in Korea, all people primarily diagnosed with MM between January 1, 2010 to December 31, 2018 were identified. A total of 9,985 MM patients aged ≥20 years in Korea were included. Among them, 237 (2.4%) developed secondary malignancies by 2018. The standardized incidence rates (SIRs) of all secondary malignancies in MM patients were 0.87 (95% confidence interval [CI]=0.76-0.98), with a higher incidence of hematologic malignancies than in the general population with an SIR of 3.80 (95% CI=2.61-5.00). The incidence rates of both lymphoid malignancy (SIR=3.56; 95% CI=2.31-4.82) and myeloid malignancy (SIR=3.78; 95% CI=1.16-6.39) were higher in MM patients than in the general population. In contrast, a lower incidence of solid cancer was observed in MM patients than in the general population (SIR=0.76, 95% CI=0.65-0.86). There was no significant difference in survival in MM patients without secondary malignancies, with hematologic malignancy, and with solid cancer (p-value=0.413). MM patients had a greater risk of secondary malignancies, especially hematologic malignancies, than the general population. Future studies with a focus on analyzing patients' history, treatment details, and genetic information in various stages of MM patients are needed to better understand the mechanism behind this increased risk.

1 January 2026 in Journal of Korean Medical Science
Verified
Journal Article
Open access
HLHaejeong Lee
Haejeong Lee
JKJi-Man Kang
Ji-Man Kang
MKMinyoung Kim
Minyoung Kim
HPHyojung Park
Hyojung Park
BNBonhyang Na
Bonhyang Na
HEHyeon-Seok Eom
Hyeon-Seok Eom
Lee H, et al. J Korean Med Sci. 2026 May;41:e141. https://doi.org/10.3346/jkms.2026.41.e141

14 August 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
WCWon Jun Choi
Won Jun Choi
JLJinhong Lee
Jinhong Lee
KCKowoon Choi
Kowoon Choi
DKDong Mi Kim
Dong Mi Kim
NHNayoung Han
Nayoung Han
ELEunyoung Lee
Eunyoung Lee
Here, we present the outcomes of four patients with COVID-19 who underwent hematopoietic stem cell transplantation (HSCT) at the National Cancer Center in South Korea. Despite concerns about the unfavorable course of COVID-19 in HSCT recipients, none of our patients experienced severe COVID-19. Moreover, extended viral shedding in case 1, lasting over 100 days, was resolved after successful engraftment. Contracting the virus when the host could not mount enough of an immune reaction might result in a paradoxically favorable course. Vaccination, monoclonal antibodies, and antiviral agent usage against COVID-19 might also be effective. We suggest, if necessary, HSCT should not be deferred in COVID-19 patients.